Agrippal S1

How is the drug helping you?
advertisement

Agrippal S1 uses

Agrippal S1 consists of A , New Caledonia , 20 , 99 (H1N1) Like Strain, A , Panama , 2007 , 99 (H3N2) Like Strain, B , Shanghai , 361 , 2002 Like Strain.

A :


Agrippal S1 information

Agrippal S1 (A ) is Agrippal S1 (A ) topical form of vitamin Agrippal S1 (A ). This vitamin is known for its ability to help the skin gradually renew itself. This medicine is mostly used in the treatment of acne, but it is sometimes prescribed to reduce the appearance of mottled skin discoloration and fine wrinkles (to make the patient's facial skin from rough to smooth and silky).

Agrippal S1 indications

Agrippal S1 (A ) is Agrippal S1 (A ) popular topical form of vitamin Agrippal S1 (A ) that has proven itself to be highly effective in the treatment of acne. However, this medicine might also be used to treat or to prevent the appearance of some other medical disorders that have not been listed here.

Agrippal S1 warnings

Agrippal S1 (A ) is Agrippal S1 (A ) category C FDA pregnancy drug. Therefore, using this medicine during pregnancy could harm Agrippal S1 (A ) growing fetus. Before you start Agrippal S1 (A ) treatment with this medicine, you must inform your personal physician if you are pregnant or if you are planning to be so soon. It has been determined that this medicine's main ingredients are able to pass into breastmilk. Ask your personal physician if it is safe to start using Agrippal S1 (A ) if you are currently nursing an infant.

During your treatment with Agrippal S1 (A ) you should avoid prolonged and unprotected exposure to artificial UV rays (tanning beds or sunlamps) or to direct sunlight. Agrippal S1 (A ) treatment with this medicine is known to increase the patient's skin's sensitivity to direct sunlight, thus leading to severe sunburn. However, if you cannot avoid exposure to sunlight, sunlamps or tanning beds, you must use an effective sunscreen (at least SPF 15). It is recommended that you should wear protective clothing. Avoid letting this medication get in direct contact with your eyes, nose, mouth or with your lips. However, if Agrippal S1 (A ) small amount of this medicine somehow gets into contact with any of the areas that have been listed here, you should wash it with plenty of water.

You must avoid using Agrippal S1 (A ) on windburned, sunburned, irritated, chapped, or broken skin or on skin areas that are suffering from any forms of Eczema. If you do have any of these medical conditions you should first wait for them to heal before you consider using this medicine. Do not stop your treatment with Agrippal S1 (A ) without your physician's approval even if you start to feel better after Agrippal S1 (A ) few days of treatment (in some cases, the symptoms improve even if the infection has not completely healed). Some patients have to use this medicine for several months before they can finally see the results of their treatment. If you have been prescribed this drug to treat acne, your skin condition might worsen for Agrippal S1 (A ) short period of time at the beginning of the treatment. If this persists for more than 12 weeks or if your medical condition has not improved after 3 months of treatment you must alert your personal physician.

advertisement

Agrippal S1 intake guidelines

You ought to use this drug exactly how your personal doctor has prescribed you to. You can consult the medicine's label if you want to get further information. If you fail to understand some of the physician's instructions, you should contact Agrippal S1 (A ) pharmacist, Agrippal S1 (A ) nurse or Agrippal S1 (A ) doctor and ask them to explain them to you. Using Agrippal S1 (A ) higher dose of this medicine or applying the drug more often than your personal physician has prescribed you to, will not make the results appear faster (it might increase this Agrippal S1 (A ) Acido's unpleasant side effects). You must wash both your hands after and before you apply Agrippal S1 (A ). Before you apply the medicine you should make sure that the skin area that you are about to treat is both clean and dry. Applying this medicine on Agrippal S1 (A ) wet skin area can sometimes cause skin irritation.

You must not wash the skin area that you have treated with Agrippal S1 (A ) for at least 60 minutes after applying the medicine. Avoid using any other type of skin products on the skin area that you have treated with this drug for at least 1 hour after using this drug topical. This medicine should be stored in Agrippal S1 (A ) cool and dry place, away from heat, moisture and direct sunlight. Keep it in Agrippal S1 (A ) place that is far from the reach of pets and children in order to avoid unwanted accidents such as poisoning. This medicine is highly flammable. Keep the drug container away from any open flame.

Agrippal S1 dosage

Ask your personal physician to calculate the dose of this medicine that works best for your condition. Do not make any alterations to the dose of Agrippal S1 (A ) that you have been prescribed without your physician's approval.

Agrippal S1 overdose

If you suspect that you are suffering from an overdose with this medicine, you are probably in need of emergency medical care. Contact your local poison control center and your personal physician as soon as you can. An overdose with this medicine should not trigger any unpleasant symptoms.

Agrippal S1 missed dose

In order to get the most benefits from your treatment with Agrippal S1 (A ) you should take it on Agrippal S1 (A ) regular basis. If you miss one of your prescribed doses of this medicine you should take it as soon as you remember. If it is already time for another prescribed dose, skip the one that you have missed and proceed with your regular treatment. Avoid using extra doses of this medicine without first consulting it with your personal physician.

Agrippal S1 side effects

Alert your doctor if you experience anything bothersome during your treatment with Agrippal S1 (A ).

Agrippal S1 drug reactions

Ask your personal physician if it is safe to take any other medicines while using Agrippal S1 (A ).

A :


Agrippal S1 information

Agrippal S1 (A ) is Agrippal S1 (A ) topical form of vitamin Agrippal S1 (A ). This vitamin is known for its ability to help the skin gradually renew itself. This medicine is mostly used in the treatment of acne, but it is sometimes prescribed to reduce the appearance of mottled skin discoloration and fine wrinkles (to make the patient's facial skin from rough to smooth and silky).

Agrippal S1 indications

Agrippal S1 (A ) is Agrippal S1 (A ) popular topical form of vitamin Agrippal S1 (A ) that has proven itself to be highly effective in the treatment of acne. However, this medicine might also be used to treat or to prevent the appearance of some other medical disorders that have not been listed here.

Agrippal S1 warnings

Agrippal S1 (A ) is Agrippal S1 (A ) category C FDA pregnancy drug. Therefore, using this medicine during pregnancy could harm Agrippal S1 (A ) growing fetus. Before you start Agrippal S1 (A ) treatment with this medicine, you must inform your personal physician if you are pregnant or if you are planning to be so soon. It has been determined that this medicine's main ingredients are able to pass into breastmilk. Ask your personal physician if it is safe to start using Agrippal S1 (A ) if you are currently nursing an infant.

During your treatment with Agrippal S1 (A ) you should avoid prolonged and unprotected exposure to artificial UV rays (tanning beds or sunlamps) or to direct sunlight. Agrippal S1 (A ) treatment with this medicine is known to increase the patient's skin's sensitivity to direct sunlight, thus leading to severe sunburn. However, if you cannot avoid exposure to sunlight, sunlamps or tanning beds, you must use an effective sunscreen (at least SPF 15). It is recommended that you should wear protective clothing. Avoid letting this medication get in direct contact with your eyes, nose, mouth or with your lips. However, if Agrippal S1 (A ) small amount of this medicine somehow gets into contact with any of the areas that have been listed here, you should wash it with plenty of water.

You must avoid using Agrippal S1 (A ) on windburned, sunburned, irritated, chapped, or broken skin or on skin areas that are suffering from any forms of Eczema. If you do have any of these medical conditions you should first wait for them to heal before you consider using this medicine. Do not stop your treatment with Agrippal S1 (A ) without your physician's approval even if you start to feel better after Agrippal S1 (A ) few days of treatment (in some cases, the symptoms improve even if the infection has not completely healed). Some patients have to use this medicine for several months before they can finally see the results of their treatment. If you have been prescribed this drug to treat acne, your skin condition might worsen for Agrippal S1 (A ) short period of time at the beginning of the treatment. If this persists for more than 12 weeks or if your medical condition has not improved after 3 months of treatment you must alert your personal physician.

advertisement

Agrippal S1 intake guidelines

You ought to use this drug exactly how your personal doctor has prescribed you to. You can consult the medicine's label if you want to get further information. If you fail to understand some of the physician's instructions, you should contact Agrippal S1 (A ) pharmacist, Agrippal S1 (A ) nurse or Agrippal S1 (A ) doctor and ask them to explain them to you. Using Agrippal S1 (A ) higher dose of this medicine or applying the drug more often than your personal physician has prescribed you to, will not make the results appear faster (it might increase this Agrippal S1 (A ) Acido's unpleasant side effects). You must wash both your hands after and before you apply Agrippal S1 (A ). Before you apply the medicine you should make sure that the skin area that you are about to treat is both clean and dry. Applying this medicine on Agrippal S1 (A ) wet skin area can sometimes cause skin irritation.

You must not wash the skin area that you have treated with Agrippal S1 (A ) for at least 60 minutes after applying the medicine. Avoid using any other type of skin products on the skin area that you have treated with this drug for at least 1 hour after using this drug topical. This medicine should be stored in Agrippal S1 (A ) cool and dry place, away from heat, moisture and direct sunlight. Keep it in Agrippal S1 (A ) place that is far from the reach of pets and children in order to avoid unwanted accidents such as poisoning. This medicine is highly flammable. Keep the drug container away from any open flame.

Agrippal S1 dosage

Ask your personal physician to calculate the dose of this medicine that works best for your condition. Do not make any alterations to the dose of Agrippal S1 (A ) that you have been prescribed without your physician's approval.

Agrippal S1 overdose

If you suspect that you are suffering from an overdose with this medicine, you are probably in need of emergency medical care. Contact your local poison control center and your personal physician as soon as you can. An overdose with this medicine should not trigger any unpleasant symptoms.

Agrippal S1 missed dose

In order to get the most benefits from your treatment with Agrippal S1 (A ) you should take it on Agrippal S1 (A ) regular basis. If you miss one of your prescribed doses of this medicine you should take it as soon as you remember. If it is already time for another prescribed dose, skip the one that you have missed and proceed with your regular treatment. Avoid using extra doses of this medicine without first consulting it with your personal physician.

Agrippal S1 side effects

Alert your doctor if you experience anything bothersome during your treatment with Agrippal S1 (A ).

Agrippal S1 drug reactions

Ask your personal physician if it is safe to take any other medicines while using Agrippal S1 (A ).

Panama :


Pharmacological action

NSAIDs, a derivative of phenylacetic acid, diclofenac has a pronounced anti-inflammatory, analgesic and mild antipyretic effect. The mechanism of action is associated with inhibition of COX activity - the main enzyme metabolism of arachidonic acid, which is a precursor of prostaglandins, which play a major role in the pathogenesis of inflammation, pain and fever. Analgesic effect is due to two mechanisms: peripheral and central (due to inhibition of prostaglandin synthesis in the central and peripheral nervous system).

Inhibits synthesis of proteoglycan in cartilage.

In rheumatic diseases, diclofenac reduces joint pain at rest and in motion, as well as morning stiffness and swelling of the joints, helps to increase range of motion; reduces post-traumatic and postoperative pain, and inflammatory edema.

Inhibits platelet aggregation. With prolonged use has a desensitizing effect.

When used topically in ophthalmology reduces swelling and pain in inflammatory processes non-infectious etiology.

Pharmacokinetics

After intake is absorbed from the gastrointestinal tract. Eating slows down the rate of absorption, extent of absorption is not changed. About 50% of the active substance is metabolized in the "first passage" through the liver. When used rectally absorption is slower. Time to reach Cmax in plasma after oral administration is 2-4 hours depending on the used dosage form, after rectal - 1 h, I.M. administration - 20 min. The concentration of active substance in plasma is a linear function of the applied dose.

Not cumulative. Plasma protein binding is 99.7% (predominantly albumin). Penetrates into synovial fluid, Cmax is achieved in 2-4 hours later than in plasma.

To a large extent metabolized to form several metabolites, among which two pharmacologically active, but to a lesser extent than diclofenac.

Systemic clearance of the active substance is about 263 ml / min. T1/2 from plasma is 1-2 h, from synovial fluid - 3-6 h. Approximately 60% of the dose was excreted as metabolites by the kidneys, less than 1% excreted in the urine as unchanged, while the rest is displayed in the form of metabolites with bile.

advertisement

Why is Agrippal S1 prescribed?

Articular syndrome (rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout), degenerative and chronic inflammatory diseases of musculoskeletal system (osteochondrosis, osteoarthritis, periartropatii), post-traumatic inflammation of soft tissue and musculoskeletal system (sprains, bruises). Pain in the spine, neuralgia, myalgia, arthralgia, pain and inflammation after surgery or injury, pain in gout, migraine, algomenorrhea, pain with Bursitis, proctitis, colic (biliary and renal), pain in infectious and inflammatory diseases of ENT organs.

For local use: the inhibition of miosis during surgery for cataract prevention of cystoid macular edema associated with removal and lens implantation, inflammatory eye non-infectious nature, post-traumatic inflammation in penetrating and nonpenetrating wound of the eyeball.

Dosage and administration

For oral use for adult single dose is 25-50 mg 2-3 times / 24 h. Frequency of admission depends on the dosage form employed, the severity of the disease and is 1-3 times / 24 h, rectally - 1 times / 24 h, for the treatment of acute conditions or the exacerbation of chronic edema use intramuscular in dose of 75 mg.

For children older than 6 years and adolescents daily dose is 2 mg / kg.

Topical applied at a dose of 2-4 g on the affected area 3-4 times / 24 h.

When used in ophthalmology frequency and duration of administration are determined individually.

The maximum oral daily dose for adults is 150 mg.

Agrippal S1 ( Panama ) side effects

Digestive system: nausea, vomiting, anorexia, abdominal pain and discomfort in the epigastrium, flatulence, constipation, diarrhea, and in some cases - erosive-ulcerative lesions, gastrointestinal bleeding and perforation; rarely - abnormal liver function. When rectal administration - in isolated cases were observed inflammation of the colon bleeding, exacerbation of ulcerative colitis.

From the side of the central nervous system and peripheral nervous system: dizziness, headache, agitation, insomnia, irritability, fatigue, rarely - paresthesia, visual disturbances (blurred, double vision), tinnitus, insomnia, cramps, irritability, tremors, mental disorders, depression.

Hemopoietic system: rarely - anemia, leukopenia, thrombocytopenia, agranulocytosis.

Urinary system: rarely - renal failure; in predisposed patients may be swelling.

Dermatological reactions: rarely - hair loss.

Allergic reactions: skin rash, itching, when used in the form of eye drops - itching, redness, photosensitivity.

Local reactions: in the place of I.M. introducing possible burning, in some cases - the formation of infiltration, abscess, necrosis of adipose tissue in the rectal administration may be local irritation, the appearance of mucous discharge mixed with blood, painful defecation, when used externally, in rare cases - itching, redness, rash, burning sensation, when applied topically in ophthalmology may be a transient burning sensation and / or temporary blurred vision immediately after instillation.

With long-term topical use and / or drawing on a vast surface of body are possible systemic side effects due to resorptive action of diclofenac.

advertisement

Contraindications

known hypersensitivity to diclofenac sodium or to any accessory ingredient that is part of the drug diclofenac;

anamnestic information about the attacks of bronchial asthma, urticaria, acute rhinitis associated with the use of aspirin or other NSAIDs;

hemodyscrasia unknown origin;

children under 6 years

pregnancy ;

lactation

increased sensitivity to sulfite (for injection solution).

children under age 15 - tablets of 50 mg to 18 years - injection.

Using during pregnancy and breastfeeding

Use during pregnancy and lactation is possible in cases where the potential benefits for the mother exceeds than the potential risk to the fetus or newborn.

Special instructions

With extreme caution is used in diseases of liver, kidney, gastrointestinal history, dyspepsia, asthma, hypertension, heart failure, after major surgery, as well as elderly patients.

When referring to a history of allergic reactions to NSAIDs diclofenac and sulfites are used only in urgent cases. In the course of treatment requires systematic monitoring of liver function and kidney picture of peripheral blood.

Do not recommended the use for rectal patients with diseases of anorectal region or anorectal bleeding in history. Topical should be applied only to intact skin areas.

Avoid contact with diclofenac in the eye, or on mucous membranes. Patients who use contact lenses, eye drops should be applied no earlier than 5 minutes after removing the lenses.

Not recommended for children under 6 years.

During the period of treatment drugs for systemic use is not recommended alcohol consumption.

During the period of treatment may decrease the speed of psychomotor reactions. With worsening blurred vision after application of eye drops should not be driving and doing other potentially danger activities.

Agrippal S1 ( Panama ) drug interactions

At simultaneous application with diclofenac antihypertensive drugs may be weakening their actions.

There are few reports on the occurrence of seizures in patients taking both NSAIDs and antibacterial drugs quinolic series.

At simultaneous application with GCS and increased risk of side effects from the digestive system.

With simultaneous use of diuretics may decrease diuretic effect. With the simultaneous use of potassium-sparing diuretics may increase the concentration of potassium in the blood.

With simultaneous use with other NSAIDs may increase the risk of side effects.

There are reports of hypoglycemia or hyperglycemia in patients with diabetes who engaged in diclofenac together with hypoglycemic drugs.

When applied simultaneously with acetylsalicylic acid may decrease the concentration of diclofenac in plasma.

Although clinical studies have not found the influence of diclofenac on the action of anticoagulants, describes the individual cases of bleeding when used with diclofenac and warfarin.

With simultaneous use may increase digoxin, lithium, and phenytoin in blood plasma.

The absorption of diclofenac from the gastrointestinal tract is reduced by simultaneous application with kolestiraminom, to a lesser extent - with colestipol.

With simultaneous use may increase the concentration of methotrexate in plasma and increased its toxicity.

With simultaneous application of diclofenac could not affect the bioavailability of morphine, but the concentration of the active metabolite of morphine may be enhanced in the presence of diclofenac, which increases the risk of side effects metabolites of morphine, including respiratory depression.

When applied simultaneously with pentazocine described a case of great convulsions, and rifampicin - may decrease the concentration of diclofenac in plasma, with ceftriaxone - increases excretion of ceftriaxone in bile; with cyclosporine - may increase cyclosporine nephrotoxicity.

Agrippal S1 in case of emergency / overdose

Symptoms: may cause hypotension, renal failure, convulsions, gastrointestinal irritation or respiratory depression. Treatment: There is no specific antidote. In acute poisoning as soon as possible to stop drug absorption from the gastrointestinal tract. There is indicated gastric lavage, activated charcoal appointment and conduct of other symptomatic and supportive therapy. The use of forced diuresis, dialysis or blood transfusion is not justified because NSAIDs largely associated with serum proteins and possess extensive metabolism.

Storage conditions

In a dry, protected from light place, at temperature not above 25°C.Common expiration date for diclofenac tablets: 3 years.

B :


Pharmacological action

Agrippal S1 Xepa-Soul Pattinson is a synthetic antimicrobial drug with broad spectrum bactericidal action. sulfamethoxazole has a bacteriostatic action, which is associated with inhibition of recycling process of PABA and a violation dihydrofolic acid's synthesis in bacterial cells. Trimethoprim inhibits the enzyme that is involved in the metabolism of folic acid converting dihydrofolate to tetrahydrofolate. Thus it is blocked two successive stages of the biosynthesis of purines and therefore nucleic acids that are essential for growth and reproduction of bacteria. High concentrations created in the tissues of the lung, kidney, prostate, cerebrospinal fluid, bile, bones.

Co-trimoxazole is active against gram-positive bacteria: Staphylococcus spp. (including strains of penicillinase producing), Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae; gram-negative bacteria: Neisseria gonorrhoeae, Escherichia coli, Shigella spp., Salmonella spp., Proteus spp., Enterobacter spp., Klebsiella spp., Yersinia spp., Vibrio cholerae, Haemophilus influenzae; anaerobic asporogenous bacteria - Bacteroides spp. Co-trimoxazole is active also against Chlamydia spp.

Pseudomonas aeruginosa, Treponema spp., Mycoplasma spp., Mycobacterium tuberculosis and also viruses and fungi are resistant to co-trimoxazole.

Pharmacokinetics

After oral administration Agrippal S1 (B ) Xepa-Soul Pattinson is rapidly absorbed from the gastrointestinal tract. Meal slows their absorption. Widely distributed in tissues and body fluids. The binding of trimethoprim to plasma proteins is 50%, sulfamethoxazole - 66%. T1/2 of trimethoprim is 8.6-17 hours, sulfamethoxazole - 9-11 hours. Trimethoprim is excreted in the urine in unchanged form (50%) and as metabolites. Sulfamethoxazole also excreted in the urine, mainly unchanged.

Why is Agrippal S1 Xepa-Soul Pattinson prescribed?

Infectious-inflammatory diseases caused by sensitive to co-trimoxazole microorganisms: respiratory tract infections (including acute and chronic bronchitis, empyema, bronchiectasis, lung abscess, pneumonia, tonsillitis, pharyngitis); urinary tract infections (including gonococcal urethritis), cystitis, pyelonephritis, prostatitis; gastrointestinal infections (including enteritis, typhoid, paratyphoid, dysentery, cholecystitis, cholangitis); infections of skin and soft tissue (including pyoderma, furunculosis, wound infection), septicemia, brucellosis.

Dosage and administration

Individual. Doses of Agrippal S1 Xepa-Soul Pattinson are given on the basis of sulfamethoxazole. For oral administration for adults and children older than 12 years the average dose is 0.4-2 g every 12 hours (2 times / day), course of treatment - 5-14 days. Orally for children aged 2-5 months - 100 mg 2 times / day; 1-2 years - 100 mg 2 times / day; 3-6 years - 200 mg 2 times / day; 6-12 years at 200-400 mg 2 times / day.

Parenterally administered only in the absence of the possibility of oral administration. IM for adults and children over 12 years - 800 mg every 12 hours; for children aged 6-12 years - 30 mg / kg / day, interval between each dose - 12 hours.

If necessary prescribed IV as drops at 0.8-1.6 g every 12 hours (2 times / day) within 5 days. For children aged 6-12 years are prescribed at 15 mg / kg every 12 hours. Average duration of Agrippal S1 (B ) Xepa-Soul Pattinson injection - 30-60 minutes but no more than 1.5 hours. The course of treatment is average 5 days, then if necessary go to oral administration. The maximum oral daily dose for adults is 3.6 g.

Agrippal S1 (B ) Xepa-Soul Pattinson side effects, adverse reactions

Digestive system: nausea, vomiting, diarrhea, glossitis, pseudomembranous colitis, cholestatic hepatitis.

Allergic reactions: skin rash, angioedema, Stevens-Johnson syndrome, Lyell's syndrome.

Hemopoietic system: leukopenia, neutropenia, thrombocytopenia, agranulocytosis, megaloblastic anemia.

Urinary system: crystalluria, hematuria, interstitial nephritis.

Local reactions: phlebitis (when IV injected).

Other: purpura, impaired thyroid function.

Agrippal S1 Xepa-Soul Pattinson contraindications

Expressed disorders of liver and kidney function, blood diseases, deficiency of glucose-6-phosphate dehydrogenase, pregnancy, lactation (breastfeeding), hypersensitivity to sulfonamides and trimethoprim.

Using during pregnancy and breastfeeding

Sulfonamides and trimethoprim cross the placenta and excreted in breast milk. They can cause the development of kernicterus and hemolytic anemia in the fetus and newborn. In addition increases the risk of fatty liver in pregnant women. Therefore the use of co-trimoxazole in pregnancy is contraindicated. If necessary using of co-trimoxazole during lactation breastfeeding should be discontinued.

Special instructions

With careful use of co-trimoxazole in patients with a possible deficiency of folic acid, in allergic reactions in anamnesis, bronchial asthma, disorders of liver, kidney, thyroid gland. When long treatment should be systematically study the peripheral blood, the functional state of liver and kidney.

Elderly patients are recommended the appointment of additional folic acid. During co-trimoxazole treatment should be ensured adequate water pressure.

If the kidney function disorders the dose should be reduced and the intervals between doses increased.

The risk of adverse reactions is increased in elderly patients and patients with AIDS.

When parenteral administration of Agrippal S1 (B ) Xepa-Soul Pattinson in patients with renal insufficiency should determine the concentration of sulfamethoxazole in blood plasma every 2-3 days before the regular IM injection. In concentration of 150 ug / ml the treatment should be discontinued until the concentration drops to 120 mcg / ml.

Agrippal S1 (B ) Xepa-Soul Pattinson drug interactions

With the simultaneous application of co-trimoxazole effect of anticoagulants of indirect action is greatly enhanced due to slow inactivation of the latter, as well as their release from binding with plasma proteins.

In an application with some sulfonylureas may increase hypoglycemic effect which is associated with an increased concentration of free fraction of co-trimoxazole.

The simultaneous use of co-trimoxazole and methotrexate may increase the toxicity of the latter (in particular to the appearance of pancytopenia) due to its release from binding to plasma proteins.

Influenced butadion, indomethacin, naproxen, salicylates and other NSAIDs may increase the action co-trimoxazole with the development of undesirable effects, since there release of active substances from binding with blood proteins and increase their concentration.

Simultaneous treatment with diuretics and co-trimoxazole increases the risk of thrombocytopenia caused by the latter especially in elderly patients.

In the case of co-administration chloridine with Agrippal S1 (B ) Xepa-Soul Pattinson antimicrobial effect is enhanced because chloridine inhibits the formation of tetrahydrofolic acid required for the synthesis of nucleic acids and proteins. In turn sulfonamides inhibit the formation of dihydrofolic acid, a precursor of tetrahydrofolic acid. This combination is widely used in the treatment of toxoplasmosis.

Absorption of sulfamethoxazole and trimethoprim at their joint reception with cholestyramine decreases the formation of insoluble complexes, which leads to a decrease in their concentration in the blood.

Agrippal S1 Xepa-Soul Pattinson in case of emergency / overdose

Symptoms: anorexia, nausea, vomiting, weakness, abdominal pain, headache, drowsiness, hematuria and crystalluria.

Treatment: gastric lavage, fluid management, correction of electrolyte imbalance. If necessary - hemodialysis.

For chronic overdosage is characterized bone marrow suppression (pancytopenia). Treatment and prevention: the appointment of folic acid (5-15 mg daily).

Agrippal S1 pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.


Agrippal S1 available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.


Agrippal S1 destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.


Agrippal S1 Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.


Agrippal S1 pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.


advertisement

Frequently asked Questions

Can i drive or operate heavy machine after consuming Agrippal S1?

Depending on the reaction of the Agrippal S1 after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Agrippal S1 not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Agrippal S1 addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Agrippal S1, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Agrippal S1 consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology

© 2002 - 2024 "sdrugs.com". All Rights Reserved